Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 6;18(12):2635. doi: 10.3390/ijms18122635

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of diphlorethohydroxycarmalol (DPHC) on receptor activator of nuclear factor-κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow macrophages (BMMs). (A) BMMs were cultured for four or five days in osteoclastogenic media containing macrophage-colony stimulating factor (M-CSF) (10 ng/mL) and RANKL (20 ng/mL) with or without various doses of DPHC. The cells were stained for TRAP; (B) The number of TRAP-positive multinucleated cells (MNCs) with ≥3 nuclei was scored. ** p < 0.01 versus vehicle-treated control; (C) BMMs were incubated with the indicated doses of DPHC in the presence of M-CSF (10 ng/mL) for three days. Cell viability was assessed by the cell counting kit-8 (CCK-8). TRAP: tartrate-resistant acid phosphatase; OCs: osteoclasts.

Effects of diphlorethohydroxycarmalol (DPHC) on receptor activator of nuclear factor-κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow macrophages (BMMs). (A) BMMs were cultured for four or five days in osteoclastogenic media containing macrophage-colony stimulating factor (M-CSF) (10 ng/mL) and RANKL (20 ng/mL) with or without various doses of DPHC. The cells were stained for TRAP; (B) The number of TRAP-positive multinucleated cells (MNCs) with ≥3 nuclei was scored. ** p < 0.01 versus vehicle-treated control; (C) BMMs were incubated with the indicated doses of DPHC in the presence of M-CSF (10 ng/mL) for three days. Cell viability was assessed by the cell counting kit-8 (CCK-8). TRAP: tartrate-resistant acid phosphatase; OCs: osteoclasts.